Detalhe da pesquisa
1.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 380(4): 347-357, 2019 01 24.
Artigo
Inglês
| MEDLINE | ID: mdl-30415602
2.
The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.
Diabetologia
; 64(6): 1226-1234, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33611623
3.
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Circulation
; 139(17): 2022-2031, 2019 04 23.
Artigo
Inglês
| MEDLINE | ID: mdl-30786725
4.
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Circulation
; 139(22): 2528-2536, 2019 05 28.
Artigo
Inglês
| MEDLINE | ID: mdl-30882238
5.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet
; 393(10166): 31-39, 2019 01 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30424892
6.
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
Am Heart J
; 200: 83-89, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29898853
7.
DECLARE-TIMI 58: Participants' baseline characteristics.
Diabetes Obes Metab
; 20(5): 1102-1110, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29322605
8.
Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
Circulation
; 140(18): e740-e741, 2019 10 29.
Artigo
Inglês
| MEDLINE | ID: mdl-31657959
9.
Modifiers of the Risk of Diabetes for Long-Term Outcomes After Coronary Revascularization: CREDO-Kyoto PCI/CABG Registry.
JACC Asia
; 2(3): 294-308, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36411876
10.
Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting Stents.
JACC Asia
; 1(3): 345-356, 2021 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36341224
11.
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
Lancet Diabetes Endocrinol
; 7(8): 606-617, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31196815